Stockreport
Examining BioMarin Stock After Pipeline Advances and Recent Price Rebound in 2025 [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
After a rollercoaster year, BioMarin's stock is up 4.6% this past week and 3.3% over the past month, though it's still down more than 17% for the last year. This reflects both renewed optimism and lingering caution. Much of this recent movement follows news about advances in their pipeline therapies and expanded regulatory approvals, which have reignited investor interest. Updates on key drug candidates and positive industry headlines have contributed to shifting sentiment in recent weeks. On our valuation scorecard, BioMarin earns a 4 out of 6 . This suggests it is undervalued in several key areas, yet traditional valuation methods rarely tell the whole story. Stick around as we dive into the usual approaches and reveal a smarter way to think about value at the end of the article. Find out why BioMarin Pharmaceutical's -17.3% return over the last year is lagging behind its peers. Approach 1: BioMarin Pharmaceutical Discounted Cash Flow (DCF) Analysis The Discounted Cash Fl
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.[MarketBeat]
- BioMarin Pharmaceutical (BMRN): Evaluating Valuation After Raised Guidance on Revenue Strength [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.[MarketBeat]
- 2 Reasons to Like BMRN and 1 to Stay Skeptical [Yahoo! Finance][Yahoo! Finance]
- More
BMRN
SEC Filings
SEC Filings
- 12/2/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 10/28/25 - Form 10-Q
- BMRN's page on the SEC website
- More